Immune response of CEA-transgenic mice transferred with OT-1 splenocytes and immunized with ovalbumin and adjuvant. Immune response of CEA-transgenic mice.

Slides:

Advertisements

Similar presentations

Life and Death of CD8 T Cells: A Role of IL-12

Advertisements

Figure 2. Positive selection of J15 TCR transgenic T cells specific for H60. (A) CD4 by CD8 profiles (left) of thymocytes and numbers (right) of each thymic.

Fig. 1. Level of Mac-1 expression on naive and recently activated LCMV GP33–41-specific T cells from TCR 318 transgenic mice. (A and B) Splenocytes from.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Anti-CD40 and CpG induce activation of T cells in draining lymph nodes

Identification of CD3+CD4−CD8− T Cells as Potential Regulatory Cells in an Experimental Murine Model of Graft-Versus-Host Skin Disease (GVHD) Fumi Miyagawa,

Detection of CD38+IgG1+ memory B cells adjacent to contracted GCs

Cognate interaction with antigen-specific T cells is required for the response of IgG-type memory B cells. Cognate interaction with antigen-specific T.

Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy by Fumihiko Tsushima, Sheng Yao, Tahiro Shin, Andrew Flies, Sarah.

Simple conditioning with monospecific CD4+CD25+ regulatory T cells for bone marrow engraftment and tolerance to multiple gene products by David-Alexandre.

Volume 25, Issue 11, Pages (November 2017)

Γδ T Cells Augment Rejection of Skin Grafts by Enhancing Cross-Priming of CD8 T Cells to Skin-Derived Antigen Azad Rahimpour, Stephen R. Mattarollo,

Loss of Runx2 in the T cell compartment leads to a defect in the number of CD8+ memory precursor T cells during LCMV–Armstrong infection. Loss of Runx2.

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

LV DNA, genome, and capsid are not required for DC activation and CD8+ T cell priming in vivo. LV DNA, genome, and capsid are not required for DC activation.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Volume 31, Issue 1, Pages (July 2009)

Activating anti-CD40 antibody partially mitigates the deficit in CTL generation and accumulation elicited by immunization with F/T 4T1-OVA cells. Activating.

VLPs activate DCs and antigen-specific CD8+ T cells via the STING and cGAS pathway. VLPs activate DCs and antigen-specific CD8+ T cells via the STING and.

Volume 18, Issue 3, Pages (March 2003)

STAT3 regulates IgE class switching in a Th2-type response.

Volume 36, Issue 1, Pages (January 2012)

Volume 17, Issue 3, Pages (October 2016)

Volume 39, Issue 6, Pages (December 2003)

STAT3 regulates GC and plasma cell IgE class switching in B cells.

Volume 11, Issue 3, Pages (September 1999)

Volume 29, Issue 6, Pages (December 2008)

Volume 37, Issue 3, Pages (September 2012)

Volume 20, Issue 3, Pages (March 2004)

Volume 28, Issue 5, Pages (May 2008)

Volume 13, Issue 2, Pages (February 2006)

Peptide concentration controls digital NFAT1 nuclear translocation kinetics in a responder fraction of stimulated naive OT-I cells. Peptide concentration.

T Cells with Low Avidity for a Tissue-Restricted Antigen Routinely Evade Central and Peripheral Tolerance and Cause Autoimmunity Dietmar Zehn, Michael.

Volume 14, Issue 5, Pages (February 2016)

Volume 7, Issue 2, Pages (August 1997)

Antigen-specific immune responses are enhanced in hypertension.

APCs from hypertensive mice present antigens more efficiently.

Volume 20, Issue 3, Pages (March 2012)

Volume 24, Issue 1, Pages (January 2016)

Members of IL-1 family of cytokines favor the generation of IL-3–secreting CD4+ T cells in vitro. Members of IL-1 family of cytokines favor the generation.

CD8 T cell memory alters the immune profile in enhanced HLH without altering viral load. CD8 T cell memory alters the immune profile in enhanced HLH without.

Volume 38, Issue 4, Pages (April 2013)

Volume 9, Issue 2, Pages (August 1998)

Conversion of CD11bhighCD27high NK cells into MDSCs leads to CD11bhighCD27high and CD11bhighCD27low NK cell reduction. Conversion of CD11bhighCD27high.

Geographic colocalization of PD-L1+ tumor cells with infiltrating immune cells in MCC. The predominant pattern of tumor cell PD-L1 expression is at the.

CD49b+ cells from tumor-bearing mice are more prone to conversion into MDSCs compared with naive CD49b+ cells. CD49b+ cells from tumor-bearing mice are.

Flow cytometric analysis of T cell activation.

Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but not OVA Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but.

Antigen-specific CD8+ T cells express higher levels of PD-1 in animals that received the optimized SSX2 vaccine. Antigen-specific CD8+ T cells express.

Fig. 1 OVA-releasing scaffolds concentrate OVA-specific CD4+T cells following ischemic injury. OVA-releasing scaffolds concentrate OVA-specific CD4+T cells.

Cytofluorometry analysis demonstrating the specific coating of anti-tumor Fab-HLA-A2/Flu conjugates on the surface of HLA-A2 negative tumor target cells,

5FU-induced specific activation of CD8+ T cells.

CD4+ and CD8+ TILs express surface CD137.

TILs upregulate CD137 in an HIF-1α–dependent fashion.

Whole-mount analysis of tumor induced lymphatic sprouting by confocal microscopy. Whole-mount analysis of tumor induced lymphatic sprouting by confocal.

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

Hypoxic Ag-specific CD8+ T cells are less functional and less proliferative. Hypoxic Ag-specific CD8+ T cells are less functional and less proliferative.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Cross-presentation of ova to ova-specific CD8+ T cells in vivo by ova-loaded gp96 surface-expressing tumor cells. Cross-presentation of ova to ova-specific.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

In vivo tumor targeting and biodistribution of radiolabeled anti-CEA Fab-H-2Kb/ova conjugates. In vivo tumor targeting and biodistribution of radiolabeled.

Anti–TGF-β1 antibody neutralizes APB-mediated immune suppression.

LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.

Hypoxia upregulates CD137 expression in T lymphocytes undergoing activation. Hypoxia upregulates CD137 expression in T lymphocytes undergoing activation.

Intratumoral injections of small doses of agonist anti-CD137 mAb to directly act on CD137+ TILs render systemic immunotherapeutic effects that are synergistic.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

Immunization with IR or F/T elicits activated OT-I cells of distinct phenotypes. Immunization with IR or F/T elicits activated OT-I cells of distinct phenotypes.

Expression of CAR, endogenous TCR, and target-cell receptors.

Presentation transcript:

Immune response of CEA-transgenic mice transferred with OT-1 splenocytes and immunized with ovalbumin and adjuvant. Immune response of CEA-transgenic mice transferred with OT-1 splenocytes and immunized with ovalbumin and adjuvant. (A) Kinetics of the immune response to ova peptide followed by double-color fluorescence staining with anti-CD8 FITC and H-2Kb/ova tetramer-PE. As indicated by the arrow, tumor grafting was performed 19 days after immunization. Results are expressed as the percentage of specific H-2Kb/ova over total CD8 T cells. (B) Representative FACS dot blot at the peak of response 11 days after injection. Alena Donda et al. Cancer Immun 2003;3:11 Copyright © 2003 by Jean-Pierre Mach